SNX18P23: A Drug Target / Disease Biomarker (G100132617)
SNX18P23: A Drug Target / Disease Biomarker
SNX18P23 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is Src-Nop2, and it is a member of the neurotrophic factor receptor tyrosine kinase (NTRK) family. This protein is known for its role in the regulation of neurotransmitter signaling in the brain, and it is potential drug target for various psychiatric and neurological disorders.
SNX18P23 is expressed in the brain and other nervous tissues and is involved in the regulation of neurotransmitter signaling. It is a key regulator of the neurotransmitter receptor tyrosine kinase (TrkB), which is a family of transmembrane proteins that play a central role in the regulation of neurotransmitter signaling. TrkB consists of two isoforms, TrkB1 and TrkB2, and each is composed of a unique gene product that is differentially expressed in different brain regions of the brain.
SNX18P23 is a critical regulator of neurotransmitter signaling in the brain, and it is involved in the regulation of many different neurotransmitters, including dopamine, serotonin, and norepinephrine. It is known to interact with the neurotransmitter receptor tyrosine kinase (TrkB) and to regulate the tyrosine phosphorylation of TrkB. This interaction between SNX18P23 and TrkB is important for the regulation of neurotransmitter signaling, and it is potential target for various psychiatric and neurological disorders.
SNX18P23 is also involved in the regulation of ion channels in the brain, and it is known to interact with the neurotransmitter GABA. GABA is a inhibitory neurotransmitter that plays a central role in the regulation of brain activity, and it is involved in the regulation of many different physiological processes, including sleep, anxiety, and depression. The interaction between SNX18P23 and GABA is important for the regulation of ion channels in the brain, and it is potential target for various psychiatric and neurological disorders.
In addition to its role in the regulation of neurotransmitter signaling and ion channels, SNX18P23 is also involved in the regulation of cell survival and proliferation. It is known to play a role in the regulation of cell adhesion, and it is involved in the regulation of cell survival and proliferation in various tissues of the body. The interaction between SNX18P23 and cell adhesion is important for the regulation of cell survival and proliferation, and it is potential target for various psychiatric and neurological disorders.
SNX18P23 is also involved in the regulation of inflammation in the brain, and it is known to interact with the neurotransmitter NF-kappa-B. NF-kappa-B is a transcription factor that is involved in the regulation of inflammation and other immune responses in the body. The interaction between SNX18P23 and NF-kappa-B is important for the regulation of inflammation in the brain, and it is potential target for various psychiatric and neurological disorders.
In conclusion, SNX18P23 is a protein that is involved in the regulation of neurotransmitter signaling, ion channels, cell survival and proliferation, and inflammation in the brain. Its role in these processes is important for the regulation of many different physiological processes, including the regulation of mood, anxiety, and depression. As a potential drug target, SNX18P23 is a promising target for the treatment of various psychiatric and neurological disorders. Further research is needed to fully understand the role of SNX18P23 in the regulation of neurotransmission and to develop effective treatments for psychiatric and neurological disorders.
Protein Name: Sorting Nexin 18 Pseudogene 23
The "SNX18P23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNX18P23 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
SNX18P24 | SNX18P3 | SNX19 | SNX2 | SNX20 | SNX21 | SNX22 | SNX24 | SNX25 | SNX27 | SNX29 | SNX29P1 | SNX29P2 | SNX3 | SNX30 | SNX31 | SNX32 | SNX33 | SNX4 | SNX5 | SNX6 | SNX7 | SNX8 | SNX9 | SOAT1 | SOAT2 | SOBP | SOCAR | SOCS1 | SOCS2 | SOCS2-AS1 | SOCS3 | SOCS3-DT | SOCS4 | SOCS5 | SOCS5P5 | SOCS6 | SOCS7 | SOD1 | SOD2 | SOD2-OT1 | SOD3 | Sodium channel | Sodium-Glucose Cotransporter (SGLT) | Sodium-potassium-calcium exchanger | SOGA1 | SOGA3 | SOHLH1 | SOHLH2 | Soluble (cytosolic) protein tyrosine phosphatases | Soluble guanylyl cyclase | Solute Carrier Family 12 | Solute carrier family 29 member | Somatostatin receptor | SON | SORBS1 | SORBS2 | SORBS3 | SORCS1 | SORCS2 | SORCS3 | SORCS3-AS1 | SORD | SORD2P | SORL1 | SORT1 | Sorting and assembly machinery complex | Sorting nexin | SOS1 | SOS2 | SOSS complex | SOST | SOSTDC1 | SOWAHA | SOWAHB | SOWAHC | SOWAHD | SOX1 | SOX1-OT | SOX10 | SOX11 | SOX12 | SOX13 | SOX14 | SOX15 | SOX17 | SOX18 | SOX2 | SOX2-OT | SOX21 | SOX21-AS1 | SOX3 | SOX30 | SOX30P1 | SOX4 | SOX5 | SOX5-AS1 | SOX6 | SOX7 | SOX8
